Renovorx Inc (RNXT) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Renovorx Inc   (NASDAQ: RNXT)


Renovorx Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Renovorx Inc's ROI in the second quarter of 2026?
Renovorx Inc recorded a cumulative net loss of $-1 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -12.05%.

Within the Healthcare sector Renovorx Inc achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -9.17 % 0.37 % 44.93 % 44.78 % 80.73 %
Y / Y Net Income Change TTM - - -100 % - -
Investment (TTM) in Millions 10 12 6 9 12
Return On Investment (TTM) -12.05 % -11.13 % 0 % -21.87 % -18.12 %
RNXT's Overall Ranking # # # # #
Seq. Investment Change TTM -6.31 % -5.34 % -0.18 % 2.6 % 3.53 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -1 -1 0 -2 -2

RNXT Company Profile >> Back to RNXT Roi Comparisons >> See Annual RNXT Return On Investment



Return On Investment RNXT's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 



  News about Renovorx Inc Return on Investment ROI

RenovoRx Appoints Senior Vice President to Spearhead Clinical and Commercial Growth Strategies

June 11, 2024

RenovoRx Appoints Ryan Witt as Senior Vice President to Drive Clinical and Commercial Business Development Opportunities
RenovoRx, a pioneering healthcare technology company, announced the appointment of Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships. This new role aims to emphasize RenovoRx s commitment to exploring and executing clinical and commercial business development opportunities with its therapeutic technology. With his extensive experience in the healthcare industry, Witt will play a crucial role in driving the company s growth and success.
RenovoRx Inc has been actively traded on the NASDAQ, but recently, the company s shares have been performing below expectations. Currently, the shares are trading at a significant 27.8% below the 52-week average. As the company strives to recover and regain investor confidence, the appointment of Ryan Witt marks a potentially compelling turning point.

RenovoRx Appoints Ryan Witt as Senior Vice President, Aiming to Strengthen Corporate Strategy and Drive Partnerships

June 10, 2024



RenovoRx, an innovative therapeutic technology company, has made a strategic move in appointing Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships. This newly created role signifies RenovoRx s firm commitment to exploring and capitalizing on clinical and commercial business development opportunities.
Key Facts:
1. RenovoRx s Net Loss and ROI: Renovorx Inc. reported a cumulative net loss of $-8 million in the first quarter of 2024, resulting in a negative ROI of -306.27%. This indicates a financial setback and necessitates an evaluation of the company s overall performance.





Financial Statements
Renovorx Inc's II. Quarter Investments $ 10 Millions RNXT's Balance sheet
Renovorx Inc's II. Quarter Income $ -3 Millions Quarterly RNXT's Income Statement
RNXT's Income by Division See RNXT's Income by Division


RNXT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 6 6 0 7 15
Y / Y Investment Growth -1.22 % 2033.68 % -95.99 % -52.67 % -
Net Income in Millions 0 0 -10 -10 -6
Y / Y Net Income Growth - - - - -
Annual Return On Investment 0 % 0 % -3516.15 % -136.12 % -41.2 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RNXT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RNXT's Competitors
Subscribers only: Roi for Renovorx Inc's Suppliers
Subscribers only: Return On Investment for RNXT's Customers

Other Ratios
RNXT's Roa RNXT's Inventory Turnover Ratio RNXT's Growth Rates RNXT's Dividend Statistics
RNXT's Profitability Ratios RNXT's Asset Turnover Ratio RNXT's Dividend Growth
RNXT's Roe RNXT's Valuation Ratios RNXT's Financial Strength Ratios RNXT's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:41:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.